Anavex Secures Proxy Contest Victory
Anavex Life Sciences Corp. successfully defended a proxy contest launched by PVG Asset Management, which sought to replace the entirety of the Company's Board at the 2026 Annual Meeting of Shareholders. Anavex announced the preliminary voting results of its 2026 Annual Meeting, at which shareholders decisively supported the Company's director nominees and strategic direction. The outcome underscored shareholder confidence in Anavex's leadership team, board oversight, and continued execution of its clinical and corporate strategy, while affirming support for the Company's long-term vision to advance innovative therapies for neurodegenerative and neurodevelopmental disorders.
The Simpson Thacher team advised members of the board of directors on aspects of the proxy contest, led by partner Christopher Ludwig, the Head of Simpson Thachers’ Shareholder Activism practice.